RT Journal Article
SR Electronic
A1 Hoyle, Brian
T1 Advances and Potential in Treatment of Hemophilia A
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 21
SP 12
OP 13
DO 10.1177/1559897715599526
UL http://mdc.sagepub.com/content/15/21/12.abstract
AB Treatment of hemophilia A is benefiting from extended half-life recombinant factor VIII compounds that maintain higher trough levels of drug with less frequent dosing. A variety of pegylated recombinant factor VIII compounds are available. A promising avenue of treatment is the targeted use of liver mesenchymal stem cells that produce factor VIII.